Dr. Falk PharmaFalk Foundation
  • About us
    About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Partnering
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence
  • Events
    Events
    • Falk Forums
    • Falk Futures
    • Symposia
  • Falk Foundation Awards
    Falk Foundation Awards
    • Falk Foundation / Guts UK Awards
    • Falk Foundation Awards Ireland
    • Falk Foundation / BASL Awards
  • Product Overview
    Product Overview
    • Budenofalk®
    • Jorveza®
    • Salofalk®
    • Ursofalk®
  • Healthcare Professionals
    Healthcare Professionals
    • Eosinophilic Oesophagitis (EoE)
    • Inflammatory Bowel Diseases
    • Liver Diseases
    • Falk News
    • Our Apps
    • FalkPlus
    • Resources
  • Patient Support
    Patient Support
    • Eosinophilic Oesophagitis (EoE)
    • Inflammatory Bowel Diseases
    • Liver Diseases
    • Patient Apps
  • Falk+
Search
Please choose your country
  • Global (English)
  • Australia
  • België (Vlaams)
  • Belgique (Français)
  • Deutschland
  • España
  • France
  • Ireland
  • Italia
  • Luxembourg (Français)
  • Nederland
  • Österreich
  • Portugal
  • Россия
  • Schweiz (Deutsch)
  • Suisse (Français)
  • United Kingdom
more info

Contact:
Phone:+44 (0)1628 536600 Email: office@drfalkpharma.co.uk

  • Contact
  • Newsroom
  • Our Partnerships
  • Falk Foundation
  • Reporting misconduct
  • Declaration
  • Reporting Adverse Events
  • Basket
  • My Account
  • Follow us on X
  • Follow us on Linkedin
Login
  • About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Partnering
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence
  • Events
    • Falk Forums
    • Falk Futures
    • Symposia
  • Falk Foundation Awards
    • Falk Foundation / Guts UK Awards
    • Falk Foundation Awards Ireland
    • Falk Foundation / BASL Awards
  • Product Overview
    • Budenofalk®
    • Jorveza®
    • Salofalk®
    • Ursofalk®
  • Healthcare Professionals
    • Eosinophilic Oesophagitis (EoE)
    • Inflammatory Bowel Diseases
    • Liver Diseases
    • Falk News
    • Our Apps
    • FalkPlus
    • Resources
  • Patient Support
    • Eosinophilic Oesophagitis (EoE)
    • Inflammatory Bowel Diseases
    • Liver Diseases
    • Patient Apps
  • Falk+
  • Contact
  • Newsroom
  • Our Partnerships
  • Falk Foundation
  • Reporting misconduct
  • Declaration
  • Reporting Adverse Events
  • Basket
  • My Account
  • Follow us on X
  • Follow us on Linkedin
Contact:
Phone:
+44 (0)1628 536600
Email:
office[at]drfalkpharma.co.uk
  • Homepage
  • Search

Search results

189 results

  • Declaration of payments made
    Declaration of payments made Homepage Declaration In accordance with the ABPI and IPHA Code of Practice for the Pharmaceutical Industry, Dr. Falk Pharma UK Ltd declares payments made to UK / IE…
  • 2025 Award Winners
    The Winners Dr. Falk / Guts UK Homepage Dr. Falk Awards Dr. Falk / Guts UK Awards 2025 Award Winners 2025 Award Winners Dietitian Recognition Award Chloe McMurray University Hospital North Tees…
  • 2024 Award Winners
    The Winners Dr. Falk / Guts UK Homepage Dr. Falk Awards Dr. Falk / Guts UK Awards 2024 Award Winners 2024 Award Winners Dietitian Recognition Award Ms Leah Seamark Somerset NHS Foundation Trust…
  • Events
    Events Homepage Events For more details about our events, please log into your account. Login
  • NEWSROOM
    Positive results from pivotal phase 3 trial on norucholic acid in PSC
    The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam
  • NEWSROOM
    New General Manager for Dr. Falk Pharma UK
    We are pleased to announce a significant leadership change in our UK/IE affiliate. After over 20 years of dedicated service, Anthony McFadyen ("Tony") will retire as General Manager in May 2025.
  • NEWSROOM
    EASL 2025
    Join us from 7 – 10 May 2025 at the EASL Congress 2025 in Amsterdam, the Netherlands or online.
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • »
Falk Foundation

Discover the range of continuing education opportunities for physicians and pharmacists provided by the Falk Foundation e.V.

Dr. Falk Pharma UK

Dr. Falk Pharma is the expert in digestive and metabolic medicine. As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being.

  • About us
  • Events
  • Contact
  • Reporting misconduct
  • Basket
  • Products
  • Patients
  • Social Media Community Guidelines
  • Reporting Adverse Events
© 2026 Dr. Falk Pharma UK Ltd | Company Registration Number: 2307698
  • Privacy Policy
  • Terms & Conditions
Notice

This website is an international information resource intended for healthcare professionals outside the United States (US) and United Kingdom (UK).

I am a health care professional outside the US and UK.

Accept
UK Login
Notice
I confirm I am a UK or Irish resident and have been prescribed either Budenofalk®, Jorveza®, Salofalk® or Ursofalk®
Accept

You are now leaving uk.drfalkpharma.com for an external website.

Dr Falk Pharma UK accepts no responsibility for the content of other websites.